Ambrx Biopharma
(NASDAQ) AMAM
This security has been delisted. This page is retained for historical reference.
AMAM News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAMAM Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-8%
Net Income Margin
-11%
Return on Equity
-51%
Return on Capital
-44%
Return on Assets
-53%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$7.40M
Operating Income
-$57.08M
EBITDA
-$63.17M
Operating Cash Flow
-$68.68M
Capital Expenditure
-$1.05M
Free Cash Flow
-$69.73M
Cash & ST Invst.
$84.48M
Total Debt
$11.98M
Ambrx Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$53.00K
-97.6%
Gross Profit
$53.00K
-97.6%
Gross Margin
100.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
87
N/A
Net Income
-$22.99M
-73.5%
EBITDA
-$25.25M
-202.7%
Quarterly Fundamentals
Total Cash
$225.26M
+166.6%
Total Debt
$10.52M
N/A
Accounts Receivable
$2.36M
+526.9%
Inventory
$5.39M
+539399900.0%
Long Term Debt
$8.61M
N/A
Short Term Debt
$1.92M
N/A
Return on Assets
-53.07%
N/A
Return on Invested Capital
-43.80%
N/A
Free Cash Flow
-$19.18M
-20.7%
Operating Cash Flow
-$18.88M
-19.6%